

International Congress VacciPharma 2023, June 17-21, 2023
Iberostar Selection Varadero Hotel



Saturday, 17 June	Time		Day1 /Sunday, 18 June		Day 2/ Monday, 19 June		Day 3/ Tuesday, 20 June		Wednesday, 21 June
			Room Varadero	Room Matanzas	Room Varadero	Room Matanzas	Room Varadero	Room Matanzas	
Travel Havana -Varadero	9:00-13:30	Symposium Oral Presentations:	Conjugate Vaccine and innovative vaccines. (Pneumococcal session)	Vaccine evaluation (QC, QA and Regulatory)	Covid-19 vaccines	3Rs methods for QC	Viral Vaccines (Polio session)	Covid-19 clinical studies	Travel Varadero-Havana
			Break	Break	Break	Break	Break	Break	
	Conjugate Vaccine and others innovative vaccines	Vaccine evaluation (QC, QA and Regulatory)	Covid-19 vaccines	3Rs methods for QC	Bioprocess	Covid-19 clinical studies			
	13:30-14:55		Lunch	Lunch	Lunch	Lunch	Lunch	Lunch	
	15:00-17:00	Symposium Digital Poster Presentations:	Conjugate Vaccine and others innovative vaccines	Vaccine evaluation (QC, QA and Regulatory)	Covid-19 vaccines	First Clinical Studies session of Posters	Bioprocess	Second Clinical Studies session of Posters	
Venue Information Program Presentation Mario Landys Chovel. Cuba	17:00-17:30					17:00-17:30	Lessons learned from the Covid-19 pandemic. Key Lecture. Dr. José Moya. PAHO		
Key lecture Dr. Vicente Verez Bencomo. FVI. Cuba	17:30-18:00					17:30-18:00	Vaccipharma 2023 closing. Mario Landys Chovel, Cuba		

Day 1 /Sunday, 18 June

ROOM VARADERO: Morning Session. Conjugate Vaccine and innovative vaccines. Symposium Program	
(25min each) Time	ORAL Conferences: Title/Speaker
9:00-9:10	Opening Pneumococcal session Chairman: Dra. Dagmar García Rivera & Dra. María Felicia Casanova González
9:10-9:35	The development strategy of the Cuban vaccine against pneumococci Yuri Valdés Balbin. FVI. Cuba
9:40-10:05	The clinical assessment strategy: Role of sentinel surveillance and Assessment in preschool children. Safety, immunogenicity and protective efficacy results of Cuban PCV Dra. María Eugenia Toledo-Romani. IPK. Cuba
10:10-10:35	Changes in nasopharyngeal colonization associated with vaccination in preschool children and Impact of the vaccination campaign in Cienfuegos on preschool children. Dra. María Eugenia Toledo-Romani. IPK.Cuba
10:40-11:05	Cuban PCV7-TT evaluation in infants: Evidence of safety, immunogenicity and protective efficacy Dagmar García Rivera. IFV. Cuba
11:10-11:35	New generations of pneumococcal vaccines after PCV7-TT/. Darielys Santana Mederos. FVI.Cuba
11:40-11:55	Break
12:00-12:25	(recorded) Global Vaccinations and the "Antipoverty Vaccines": The Science vs The Antiscience. Dr. Peter Hotez. Texas Children's Hospital Center for Vaccine Development. USA.
12:30-12:55	RSV F protein as target for vaccines. Françoise Paquet. Centre de Biophysique Moléculaire, CNRS Orléans. France
13:00-1:25	Synthetic oligosaccharide conjugate pertussis vaccine candidate against nasopharyngeal colonization. Sonsire Fernández Castillo. FVI. Cuba
13:30-14:55	Lunch

ROOM VARADERO: Evening Session. Conjugate Vaccine and innovative vaccines. Symposium Program

Time 15:00-17:00 Digital Poster Presentations

Chairman: Dra. Dagmar García Rivera & Dra. María Felicia Casanova González

(10 min each) Time	Poster Presentation (TV1-Product)	Poster Presentation (TV2-Clinical)
15:00-15:10	Evaluation of a new culture medium for obtaining capsular polysaccharide from <i>Streptococcus pneumoniae</i> serotype 15B and 22F. Maritza Hernández. FVI. Cuba	Prevalence of nasopharyngeal colonization of <i>Streptococcus pneumoniae</i> in vaccinated healthy children and cohabiting cohorts of infants and adults over 65 years of age. Aniurka Garcés. FVI. Cuba
15:15-15:25	Purification of capsular polysaccharides from <i>Streptococcus pneumoniae</i> serotypes 6B and 23F using a monolithic CIM DEAE. Abel Alfonso. FVI. Cuba	Surveillance of invasive pneumococcal disease in patients under 5 years of age discharged from the Cienfuegos Pediatric Hospital 2014-2022. Dra. Mercedes Fonseca. MINSAP Cienfuegos. Cuba
15:30-15:40	Synthesis of anionic nanoparticles based on iron oxides as potential supports for magnetic bioseparation. Daniel Díaz Casas. FVI. Cuba	Characterization of patients with Bacterial Pneumonia in the Pediatric Hospital of Cienfuegos. Dra. Ma Felicia Casanova. MINSAP Cienfuegos. Cuba
15:45-15:55	Conjugation procedures of four <i>Streptococcus pneumoniae</i> serotypes as part of a new Cuban multivalent conjugate vaccine for young children. Jean Pierre Soubal Mora. FVI. Cuba	Sentinel surveillance for the detection and isolation of <i>Streptococcus pneumoniae</i> . Dra. Kenia Carrandia Acosta. MINSAP Cienfuegos. Cuba
16:00-16:10	Evaluation of the impact of yeast extract from different suppliers and references, on the growth of <i>Neisseria meningitidis</i> serogroup W 135, on the production of capsular polysaccharide, API of the Vax-MEN-ACW vaccine. Gabriel Molina. FVI. Cuba	Surveillance of nasopharyngeal colonization by pneumococcus. Dunia M. Chávez Amaro. MINSAP Cienfuegos. Cuba
16:15-16:25	Expression in E. Coli of CRM-197: A carrier protein in vaccines formulation. Jorge González-Bacerio. UH. Cuba	Early effect of pneumococcal vaccination in preschool children on pneumococcal disease in Cienfuegos. 2009-2019. Antonio Masot-Rangel MINSAP Cienfuegos. Cuba
16:30-16:40	Synthetic oligosaccharides for cancer vaccines. Hilda María Alarcón Ríos. FVI. Cuba	
16:45-16:55	Synthesis and characterization of nanometric Cu(I) catalysts to obtain MenW ₁₃₅ -TT conjugates by Huisgen cycloaddition reaction. Daniel Díaz Casas. FVI. Cuba	

Day1 /Sunday, 18 June

ROOM MATANZAS: Morning Session. Vaccine evaluation (QC, QA and Regulatory) Symposium Program	
(25min each) Time	ORAL Conferences: Title/Speakers
9:00-9:10	Opening Address Chairman: Dra. Danay Mora Pascual & Dra. Biorkys Yañez Chamizo
9:10-9:35	Recent developments in regulatory approaches for vaccines in the American Region. Nora Dellepiane. Consultant. Argentina
9:40-10:05	An overview on updated GMP requirements for sterile medicinal products. Biorkys Yañez Chamizo. GMP Advisor. Instituto Mechnikov. Nicaragua
10:10-10:35	Application of proteomics tools to vaccine characterization. Luis Javier Gonzalez. CIGB.CUBA
10:40-11:05	Characterization of biomolecules using light scattering techniques. Jessy Pedroso Fernandez. IFV. Cuba
11:10-11:35	NMR experiment oriented to the characterization of API and components of vaccines. Raine Garrido Arteaga. FVI. Cuba
11:40-11:55	Break
12:00-12:25	Development of an In-house serological method to evaluate the immunogenicity of Soberana® vaccines. Lucy Herrera Guada. FVI. Cuba
13:00-14:55	Lunch

ROOM MATANZAS: Evening Session. Vaccine evaluation (QC, QA and Regulatory) Symposium Program		
Time 15:00-17:00 Digital Poster Presentations		
Chairman: Dra. Danay Mora Pascual & Dra. Biorkys Yáñez Chamizo		
(10 min each) Time	Poster Presentation (TV1-QC)	Poster Presentation (TV2-QA& QC)
15:00-15:10	Determination of the isoelectric point of the RBD reference material for the release of the API samples of the vaccine against Covid-19. Lemus Raydan. CIGB. Cuba	Experiences in assessment of vaccine from CTD format. Erich Duque Gil. CECMED. Cuba
15:15-15:25	Establishment of two chromatographic methods to evaluate the conjugation process of the RBD-TT and the pneumococcus monovalent conjugates. Yalaidys Plutin. FVI. Cuba	Strategy for the preparation of Soberana® vaccine dossier, from the clinical trials phases to the emergency's authorization use. Ivis Ontivero. FVI. Cuba
15:30-15:40	Conjugation of two ANTI-RBD monoclonal antibodies of Sars-CoV-2 virus and its applicability in sandwich ELISA for the quantification of protein in active pharmaceutical ingredient batches of Soberana®02 vaccines. Raquel Mujica. FVI. Cuba	Design and implementation a methodology for lot release of acquired biological raw material rbd and apis of soberana® vaccines. Tania García. FVI. Cuba
15:45-15:55	Evaluation of the content of endotoxins by LAL in inherently pyrogenic vaccines. Danay Díaz Antúnez. FVI. Cuba	Quality assurance of Soberana® vaccines Bertha Guillén. FVI. Cuba
16:00-16:10	Dot-blot as an analytical tool for determining identity in vaccines. Deidad Brooms. FVI. Cuba	Quality Assurance for the Covid-19 vaccine formulations produced at AICA. Jessica Olivia Candia. AICA. Cuba
16:15-16:25	Repeated toxicity test (112 days) of the prolinem-bt antialergic vaccine by subcutaneous route in rats CENP:OFA (SD). Preliminar results. Yana González CENPALAB. Cuba	Validation of the cleaning and disinfection process of areas at the Finlay Institute of Vaccines. Daily Hernández. FVI. Cuba
16:30-16:40	Characterization of the FVI <i>Clostridium tetani</i> Harvard Caracas 80 strain collection. Nadiesda Baños. FVI. Cuba	Establishment of an HPLC-SEC method to determine molecular integrity in SOBERANAS vaccines. Yalaidy Plutin. FVI. Cuba
16:45-16:55	Establishment of a guinea pig serological (ELISA) assay to evaluate the potency of diphtheria and tetanus vaccines. Orialis Valle. FVI. Cuba	Development of a sandwich ELISA as an alternative to the inhibition ELISA for quantification of polysaccharide Vi Jaqueline Veliz Rivera. FVI. CUBA

Day2 /Monday, 19 June

ROOM VARADERO: Morning Session. Covid-19 vaccines Symposium Program	
(20min each) Time	ORAL Conferences: Title/Speaker Chairmans: Dra. Sonsire Fernández Castillo & Dr. Gerardo Guillén Nieto
9:00-9:20	Current state of Covid-19 and Covid-19 vaccines in the US. Dr. William Blanchet. USA.
9:25-10:45	Development of an RBD-Tetanus Toxoid conjugate anti-Covid 19 vaccine (Soberana®02): Design and preclinical proof of concept. Sonsire Fernández Castillo. IFV. Cuba
10:50-11:10	Production of more than 50 million doses of the Active Pharmaceutical Ingredient of the recombinant protein of the receptor binding domain (RBD) of the SARS-CoV-2 virus for the manufacture of the Abdala vaccine. Gerardo Guillen Nieto. IFV. CUBA
11:15-11:35	Cuban nasal vaccine Mambisa against COVID-19. Gerardo Guillen Nieto. CIGB. CUBA
11:40-12:00	The safety and quality evaluation for lot release certification of Covid-19 vaccines imported and used in Nigeria from March 2021 to March 2022. Prof Moji Christianah Adeyeye (NAFDAC) Nigeria
12:05-12:15	Break
12:15-12:35	Chimeric antigens produced in HEK-293 cells bases on Sars-CoV2 and RBD proteins fused to extracellular domain of humen CD154. Thailin Lao. CIGB.CUBA
12:40-13:00	Strategy for developing vaccines against COVID-19 based on dimeric RBD. Darielys Santana Mederos. Cuba
13:05-13:25	A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies. Franciscary Pi-Estopiñan. CIM. Cuba
13:30-14:55	Lunch

ROOM VARADERO: Evening Session. Covid-19 vaccines Symposium Program		
Time 15:00-17:00 Digital Poster Presentations		
Chairman: Dra. Sonsire Fernández Castillo & Dr. Gerardo Guillén Nieto		
(10 min each) Time	Poster Presentation (TV1-Product)	Poster Presentation (TV2-preclinical)
15:00-15:10	Monitoring and intelligence strategy for the development of Soberana vaccines. Randelis Molina. FVI. Cuba	General program and toxicological preclinical designs of Abdala vaccine. Jorge Castro Velazco. CIGB. Cuba
15:15-15:25	Scale-up of the conjugation process of the receptor binding domain (RBD) to tetanus toxoid, active pharmaceutical ingredient of the Soberana® 02 vaccine. Kenia Reyes. FVI. Cuba	General considerations for design and conduct of toxicity studies in juvenile's animals, Abdala vaccine, first study. Lizet Aldana. CIGB. Cuba
15:30-15:40	Physico-chemical and biological characterization of the dimeric RBD protein produced in center of molecular immunology. Grettel Marrero. CIM. Cuba	A nasal vaccine candidate against covid-19 based on RBD and N antigens combined with the c-di-AMP as immunomodulator induces systemic and mucosal immune responses in BALB/c mice. Iris Valdés. CIGB. Cuba
15:45-15:55	Obtaining and characterization of immunogenic RBD-TT conjugates for active pharmaceutical ingredient of the SOBERANA 02 vaccine. Lauren M. Quintero Moreno. FVI. Cuba	Nasal booster with Mambisa increase systemic functional antibody response in Abdala vaccinated monkeys. Ingrid Rodríguez Alonso. CIGB. Cuba
16:00-16:10	Consistency of production of Soberana® 02 and Soberana® plus vaccines. Yanaisy Troya. FVI. Cuba	Repeated-dose toxicity and immunogenicity of vaccine candidates against Sars-CoV-2 in cercopithecus aethiops. Axel Mancedo. CENPALAB. Cuba
16:15-16:25	Characterization by LC-MS/MS of Soberana-02: An effective RBD-tetanus toxoid conjugate vaccine against SARS-CoV-2. Olivia Martínez-Armenteros. FVI. Cuba	Non-clinical assay: Repeated dose toxicity and local tolerance of the anti-SARS-CoV-2 vaccine candidate FINLAY-FR-02 conjugated to tetanus toxoid and absorbed in aluminum hydroxide in Sprague Dawley rats. Mildrey Fariñas. FVI. Cuba
16:30-15:40	Demonstration of the shelf life and accelerated stability for Soberana 02 vaccine in single and multidoses containers. Sucet Beoto. FVI. Cuba	SOBERANA 02 vaccine induces immunity and protection against SARS-CoV-2 in viral challenge in Syrian Golden Hamster biomodel. Nibaldo Luis González Sosa. DC. Cuba
16:45-16:55	Chemically assisted dimerization of a recombinant RBD of SARS-CoV2 spike protein as an alternative source of antigen for Soberana 01 and Soberana Plus vaccines. Lisandra Pérez Pérez. FVI. Cuba	

Day2 /Monday, 19 June

ROOM MATANZAS: Morning Session. Opportunities for the implementation of 3Rs methods for QC of vaccines in Pan-America: adoption, development, validation, integration, harmonization and regulatory acceptance Workshop	
(20min each) Time	ORAL Conferences: Title/Speaker Opening Adress / Chairmans: MSc Mario Landys Chovel & Dra. Nora Dellepiane
9:00-9:10	(Recorded) Animal use in vaccine QC and batch release and need for 3Rs To be confirmed
9:10-10:30	(Recorded) Global effort for eliminating the General Safety Test Laura Viviani (HSI). USA
10:30-10:50	3Rs application for eliminating animal safety/toxicity tests in vaccine specifications. Cuban experience. Juan Francisco Núñez. FVI. Cuba
10:55-11:15	Using the monocyte activation test (MAT) for pyrogenicity measurements. Josephine Hubloher. PEI. Germany
11:20-11:40	(Panel discussion) Implementing MAT in Pan-America. Rolando Perdomo (CIDEM, Cuba) and Alejandro Beldarraín (Merck)
11:40-10:50	Break
11:50-12:10	(Recorded) Human Rabies vaccine potency test and the test for G-protein. Eriko Terao. EDQM
12:15-12:35	The consistency approach: a change in perspective on batch release testing and a key example of multi-stakeholders' collaboration. Nora Dellepiane. QRB Consultants Sàrl. Argentina
12:40-13:00	Serological methods as alternative for in vivo potency/seroneutralization tests for D, T and wP vaccines. Mario Landys Chovel. FVI. Cuba
13:05-13:25	Reduction in the use of animals for surgical medical training through alternatives in a Pediatric Hospital. Marcelo Asprea. Argentina
13:30-14:55	Lunch

Day2 /Monday, 19 June

ROOM MATANZAS: Evening Session. Clinical studies Symposium (first poster session) Program	
Time 15:00-17:00 Digital Poster Presentations	
Chairman: Dra. María Eugenia Toledo-Romani & Dr. Rinaldo Puga Gómez	
(10 min each) Time	Poster Presentation (TV1-Non Covid 19)
15:00-15:10	Long term evaluation of HBSAG levels in the serum of samples from chronic hepatitis b patients treated with Hebernasvac in the phase iv clinical trial. Iván Luis Santos. CIGB. Cuba
15:15-15:25	Increased expression of interferon stimulated genes in human blood after Nasalferon or Hebernasvac local treatment. Jorge Aguiar. CIGB. Cuba
15:30-15:40	Validation and application of an ELISA for the quantification of human IgG antibodies against <i>Neisseria meningitidis</i> serogroup B outer membrane proteins. Yamilka Soroa Millán. FVI. Cuba
15:45-15:55	Standardization of an ELISA for the quantification of human IgG antibodies against whole cells of Bordetella pertussis. Dayle Martínez-Bedoya. FVI. Cuba
16:00-16:10	Surveillance of adverse events to vax-TET® - 5, vax-TyVi® and VA-MENGOC-BC® vaccines. Cuba, 2017-2022. Claudia Verena Fundora García. FVI. Cuba
16:15-16:25	Meta-analysis for the pharmacokinetics evaluation of Nimotuzumab. Carmen Viada. CIM. Cuba

Day3 / Tuesday, 20 June

ROOM VARADERO: Morning Session. Viral Vaccines symposium (Polio session) Program	
(20min each) Time	ORAL Conferences: Title/Speaker Chairman: Dra. Sonia Resik & Dr. Ondrej Mach
9:00-9:20	Global Polio Eradication Update Dr. Ondrej Mach. WHO
9:25-10:45	The use of novel vaccines for the Global Polio Eradication Initiative. Javier Martin. NIBSC. UK
10:50-11:10	New Cuban contributions to the Global Polio Eradication Program. Dra. Sonia Resik. IPK. Cuba
11:15-11:35	Polio serology results in two provinces after fIPV administration by Tropis or Needle and Syringe in Cuba. Dra. Alina Tejeda. Cuba
	Symposium end & Break
ROOM VARADERO: Morning Session. Bioprocess Symposium Program	
(20min each) Time	ORAL Conferences: Title/Speaker Chairman: MSc. Humberto González Rodríguez & Dra. Yaneli Herrera Rojas
11:40-12:00	(Recorded). Innovative technology transfer models to advance a Covid-19 vaccine for global access. Dr. Maria Elena Bottazi. Texas Children's Hospital Center for Vaccine Development, USA
12:05-12:25	mRNA-Based human vaccines. An overview. Javier Vázquez. Instituto Mechnikov. Nicaragua
12:30-12:50	Approach to enabling biopharmaceutical manufacturing ramp-up. Daniel Cardoso. BIOZEEN. India
12:55-13:15	Validation of a mathematical model of large-scale culture for mammalian cells. Alejandro González Álvarez. CIM. Cuba
13.20-13:40	Impact of culture media on the physics-chemical and biological properties of Anti-CD20 monoclonal antibody. Gabriela Garcia. CIM. Cuba
13:45-14:55	Lunch

ROOM VARADERO: Evening Session. Bioprocess Symposium Program

Time 15:00-17:00 Digital Poster Presentations

Chairman: MSc. Humberto González Rodríguez & Dra. Yaneli Herrera Rojas

(10 min each) Time	Poster Presentation (TV1)
15:00-15:10	Technological improvements applied to the purification process of recombinant IFN gamma protein on an industrial scale. Yenlis Rodríguez. CIGB. Cuba
15:15-15:25	Design of new production plants according to GMP requirements, for the production of Sterile Purified Diphtheria Anatoxin, Bordetella Pertussis Inactivated Cell Concentrate and Sterile Purified Tetanus Anatoxin: Conceptual engineering. José Daniel Benítez. FVI. Cuba
15:30-15:40	Recent FVI experiences in Technology Transfer. Yaneli Herrera Rojas. FVI. Cuba

Day3 / Tuesday, 20 June

ROOM MATANZAS: Morning Session. Covid-19 vaccines clinical studies Symposium Program	
(15min each) Time	ORAL Conferences: Title/Speaker Chairman: Dra. María Eugenia Toledo Romani & Dr. Rinaldo Puga Gómez
9:00-9:15	(Panel discussion) Modifications to the regulatory actions for the authorization of Cuban vaccines against Covid-19, lessons learned19. Dr. Jorge Menéndez and Diadelis Remírez Figueredo. CECMED. Cuba
9:20-9:35	Methodological strategy for the use of adaptive designs in therapeutic and prophylactic clinical trials in Cuba. Carmen Valenzuela Silva. ICIMAF. CUBA
9:40-9:55	Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomized, placebo-controlled phase 3 clinical trials. Dra. Ma Eugenia Toledo Romani. IPK. Cuba
10:00-10:15	Abdala vaccine in pediatric ages: a double-blinded, multicentre, randomized, phase 1/2 clinical trial (ISMAELILLO study). Dra. Zurina Cinza-Estévez. CIGB. Cuba
10:20-10:35	Clinical development of SOBERANA 02 and SOBERANA Plus as a heterologous regimen for the pediatric population. Dra. Dagmar García Rivera. FVI. Cuba
10:40-11:00	Break
11:00-11:15	Humoral and cellular immune response after vaccination with SOBERANA® 02 and SOBERANA® Plus heterologous scheme in children. Rocmira Pérez Nicado. FVI. Cuba
11:20-11:35	Real-world effectiveness of the SOBERANA-02 with SOBERANA-Plus vaccine scheme in children 2 to 11 years old during the SARS CoV-2 Omicron wave in Cuba. Dra.Ma Eugenia Toledo Romani. IPK. Cuba
11:40-11:55	SOBERANA® Plus, safe and immunogenic vaccine for Covid-19 convalescents. Rolando Ochoa. FVI. Cuba
12:00-12:15	Severe illness for Covid 19. Impact of immunization. Dra. Lilia María Ortega. IPK. Cuba
12:20-12:35	Safety behavior of the heterologous scheme with SOBERANA 02 and SOBERANA Plus, in children from 2 to 18 years old during EUA in Cuba. September 2021-December 2021. Dra. Mery Martínez. FVI. Cuba
12:40-12:55	Immunogenicity of heterologous vaccination regimen with inactivated BBIBP-CCORV vaccine (Sinopharm) and SARS-COV-2 Dimeric-RBD recombinant (SOBERANA Plus). Laura Rodríguez Noda FVI. Cuba
13:00-14:55	Lunch

ROOM MATANZAS: Evening Session. Covid-19 vaccines Symposium (second poster session) Program

Time 15:00-17:00 Digital Poster Presentations

Chairman: Dra. Maria Eugenia Toledo-Romani & Dr. Rinaldo Puga Gómez

(10 min each) Time	Poster Presentation (TV1-Methods)	Poster Presentation (TV2-CT)
15:00-15:10	Use of the UMELISA assays in the clinical trials and others studies conducted with the cuban vaccines against Covid-19. Ariel Palenzuela. CIE. Cuba	Vaccination of Covid-19 convalescent children with single dose of Soberana Plus. Dr. Rinaldo Puga-Gómez. MINSAP. Cuba
15:15-15:25	Analysis of anti-N and anti-RBD antibody titers in a population vaccinated with Abdala and Soberana. Darien Ortega. CIE. Cuba	A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD Covid-19 vaccine candidates: safety, reactogenicity and immunogenicity. Meiby de la Caridad Rodríguez. FVI. Cuba
15:30-15:40	Development of an Elisa-type assay for the assessment of the avidity of antibody produced by vaccination in convalescents with booster doses with Mambisa and Abdala. Gilda Lemos-Pérez. CIGB. Cuba	Safety and immunogenicity of anti-Sars-CoV-2 vaccine Soberana® 02 in homologous or heterologous scheme: open label phase I and phase IIa clinical trials. Narciso Jiménez. FVI. Cuba
15:45-15:55	Characterization of cellular response in Abdala vaccinated individuals by elispot and flow cytometry. Ricardo Ulises Martínez. CIGB. Cuba	Safety and immunogenicity of anti-sars-cov-2 heterologous scheme with Soberana 02 and Soberana plus vaccines: phase IIb clinical trial in adults. Betty Paredes. FVI. Cuba
16:00-16:10	Humoral and cellular immune response of subjects vaccinated with Soberana® 01/Soberana® Plus and Soberana® 02/Soberana® Plus heterologous schemes. Ilianet Palmero-Álvarez. FVI. Cuba	Soberana® Plus vaccine: effective booster for Covid-19 vaccination schedules. Rolando Ochoa. FVI. Cuba
16:15-16:25	Organization by process of clinical trials of Soberanas vaccines. Marisel Martínez. FVI. Cuba	Clinical characterization of a group of people convalescent from Covid-19 recovered in the institute of tropical medicine "Pedro Kouri" and effectiveness of anti-Sars-Cov-2 vaccines for long covid. Narciso Jiménez. FVI. Cuba
16:30-15:40	Implementation of a logistic system for facing the clinical trials during the COVID-19 pandemics. Yadira Gómez. FVI. Cuba	Protection of SOBERANA® vaccines against SARS-CoV-2 variants of concern in the vaccinated Cuban population. Enrique Noa Romero. DC. Cuba
16:45-16:55		Process management as strategy for conducting the clinical trial Soberana center. Pedro Pablo Guerra. CENCEC. Cuba
17:00-17:10		A health intervention with Soberana® 02 and Soberana® Plus vaccines, in workers of the cuban biopharmaceutical sector. Nevis Amin. FVI. Cuba